"Omega-3 After the Fish are Gone? Addressing the Supply Risk for Pharmaceutical EPA"

Mr Moss-Smith is Chief Executive of Photonz Corporation Limited (New Zealand). He has 15 years senior executive, general management experience in the biopharmaceuticals sector including head of commercial operations of the successful Australian public biotechnology company, GroPep Limited,  throughout its maturation from an early stage company through its IPO, continued growth and subsequent acquisition by Novozymes A/S (Denmark). He joined the management team integrating four companies to create Novozymes Biopharma and became Global Sales Director for the newly formed business establishing and managing the worldwide sales organization based out of Cambridge, Massachusetts. He has held other positions including General Manager of Contract Manufacturing at GroPep Limited, Alternate Director of TGR Biosciences Pty Ltd, Director of the Cooperative Research Centre for Tissue Growth & Repair, Director & General Manager of Independent Biologics Ltd, Facilitator of the (NZ) National Science Strategy for Fisheries & Aquaculture and was the founding manager of the Technology for Business Growth program at the Foundation for Research, Science & Technology (NZ).